Adalimumab is a fully human monoclonal antibody (IgG1) that targets tumor necrosis factor-alpha (TNF-α), a key pro-inflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory diseases. By binding specifically to TNF-α, adalimumab prevents its interaction with TNF receptors (TNFR1 and TNFR2), thereby inhibiting downstream signaling that leads to inflammation, cell recruitment, and tissue destruction. It was the first fully human anti-TNF biologic approved for clinical use and is commonly administered subcutaneously.
Clinically, adalimumab is widely used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, and plaque psoriasis, among others. It is part of the biologic DMARDs (bDMARDs) and is especially indicated when conventional treatments (e.g., methotrexate or corticosteroids) fail. In research settings, adalimumab is utilized to explore TNF-related pathways, immune cell dynamics, and therapeutic biomarkers. Studies also focus on pharmacogenomics, immunogenicity (anti-drug antibodies), and predictive markers of response or resistance. It serves as a valuable tool for investigating cytokine networks, chronic inflammation, and drug efficacy across immune-mediated diseases.
This product is manufactured in Turkey by Matriks Biotek.
